Chongqing Zhifei Biological Products Co., Ltd. Website

Chongqing Zhifei Biological Products Co., Ltd.

SZSE-300122

Basic

  • Market Cap

    CN¥66.21B

  • EV

    CN¥68.28B

  • Shares Out

    2,393.79M

  • Revenue

    CN¥53.14B

  • Employees

    6,545

Margins

  • Gross

    25.41%

  • EBITDA

    16.56%

  • Operating

    15.98%

  • Pre-Tax

    16.34%

  • Net

    14.11%

  • FCF

    8.78%

Returns (5Yr Avg)

  • ROA

    27.14%

  • ROTA

    50.27%

  • ROE

    48.67%

  • ROCE

    56.5%

  • ROIC

    44.02%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    CN¥54.44

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    CN¥2,971.78M

  • Net Debt

    CN¥2,064.42M

  • Debt/Equity

    0.15

  • EBIT/Interest

    100.82

Growth (CAGR)

  • Rev 3Yr

    47.73%

  • Rev 5Yr

    51.39%

  • Rev 10Yr

    52.95%

  • Dil EPS 3Yr

    26.3%

  • Dil EPS 5Yr

    34.66%

  • Dil EPS 10Yr

    50.22%

  • Rev Fwd 2Yr

    9.53%

  • EBITDA Fwd 2Yr

    15.56%

  • EPS Fwd 2Yr

    21%

  • EPS LT Growth Est

    2.84%

Dividends

  • Yield

  • Payout

    25.6%

  • DPS

    CN¥0.8

  • DPS Growth 3Yr

    33.89%

  • DPS Growth 5Yr

    19.14%

  • DPS Growth 10Yr

    37.38%

  • DPS Growth Fwd 2Yr

    12.39%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Jan '23

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Operating Revenues

10,525.4

15,156.1

30,629

38,260.2

52,913.7

53,136.6

Other Revenues, Total

61.9

34.2

23.5

3.9

4.1

4.1

Total Revenues

10,587.3

15,190.4

30,652.4

38,264

52,917.8

53,140.7

Total Revenues % Chg.

102.5%

43.5%

101.8%

24.8%

38.3%

38.9%

Cost of Goods Sold, Total

6,154

9,315.8

15,727.8

25,518.3

38,996.6

39,636.7

Gross Profit

4,433.3

5,874.6

14,924.6

12,745.7

13,921.1

13,504

Selling General & Admin Expenses, Total

1,278.3

1,409.8

2,121.5

2,595.4

3,155.3

3,234.8

Provision for Bad Debts

68.1

82.9

190.7

420.9

352.6

543

R&D Expenses

169.6

299.7

552.6

854.2

968.5

988.6

Other Operating Expenses

51.4

71

135.2

177

238.7

245.2

Other Operating Expenses, Total

1,567.3

1,863.3

3,000.1

4,047.4

4,715.1

5,011.5

Operating Income

2,865.9

4,011.2

11,924.5

8,698.2

9,206

8,492.5

Interest Expense, Total

-76.1

-127.1

-56.1

-53.3

-81

-84.2

Interest And Investment Income

10.8

12

61.5

46.1

67.9

84.5

Net Interest Expenses

-65.3

-115.2

5.3

-7.2

-13.1

0.2

Income (Loss) On Equity Invest.

Currency Exchange Gains (Loss)

1.9

3.8

-10.1

15.4

2.3

2.3

Other Non Operating Income (Expenses)

-11.5

-19.6

-17.2

-22.6

-36.6

-31.6

EBT, Excl. Unusual Items

2,791.1

3,880.3

11,902.5

8,683.8

9,158.7

8,463.4

Gain (Loss) On Sale Of Investments

-1.1

-13.3

-5.6

Gain (Loss) On Sale Of Assets

0

-0

0

0

41.4

41.2

Asset Writedown

-0.7

-0.5

-1.7

-0.1

-0.1

33.4

Other Unusual Items

-23.9

-12.3

35.8

34.3

142.3

145.7

EBT, Incl. Unusual Items

2,765.4

3,854.1

11,931.1

8,718

9,342.3

8,683.8

Income Tax Expense

398.9

552.7

1,722.5

1,179

1,272.4

1,188.2

Earnings From Continuing Operations

2,366.4

3,301.3

10,208.5

7,539

8,069.9

7,495.6

Net Income

2,366.4

3,301.3

10,208.5

7,539

8,069.9

7,495.6

Net Income to Common Incl Extra Items

2,366.4

3,301.3

10,208.5

7,539

8,069.9

7,495.6

Net Income to Common Excl. Extra Items

2,366.4

3,301.3

10,208.5

7,539

8,069.9

7,495.6

Total Shares Outstanding

2,400

2,400

2,400

2,400

2,400

2,400

Weighted Avg. Shares Outstanding

2,400

2,400.1

2,400

2,400

2,400

2,398.5

Weighted Avg. Shares Outstanding Dil

2,400

2,400.1

2,400

2,400

2,400

2,398.5

EPS

1

1.4

4.3

3.1

3.4

3.1

EPS Diluted

1

1.4

4.3

3.1

3.4

3.1

EBITDA

2,954.4

4,132.2

12,296.7

9,003.1

9,514.9

8,802.4

Effective Tax Rate

14.4%

14.3%

14.4%

13.5%

13.6%

13.7%